Journal Article

Efficacy as an Important Facet of “Safety” in Clinical Trials: How Can We Do Our Best for Our Patients?

George H. Talbot

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 47, issue Supplement_3, pages S180-S185
Published in print December 2008 | ISSN: 1058-4838
Published online December 2008 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/591401
Efficacy as an Important Facet of “Safety” in Clinical Trials: How Can We Do Our Best for Our Patients?

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Ensuring optimal efficacy is an important facet of patient safety during the conduct of a clinical trial, if, by “safety,” we mean the anticipation, prevention, and assessment of any event that can have an unfavorable impact on the enrolled patients. This article addresses what could be termed the “nonsafety” aspects of safety during clinical trials, with a focus on situations in which we, as drug developers and clinical investigators, can err and thereby put our study patients at an unanticipated and unintended risk for a poor outcome. Approaches to mitigating the safety risk of efficacy are also discussed.

Journal Article.  3770 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.